Trial Profile
A Retrospective Study Investigating the Relationship between Metabolic Toxicities and mTOR Inhibitors Efficacy in Metastatic Renal Cell Carcinoma (mRCC) Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Apr 2018
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 10 Apr 2018 New trial record